Progesterone vaginal - Teva

Drug Profile

Progesterone vaginal - Teva

Alternative Names: DR-201; Milprosa

Latest Information Update: 16 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 28 Sep 2015 Progesterone vaginal ring licensed to Ferring Pharmaceuticals worldwide
  • 31 Dec 2014 Discontinued - Preregistration for Female infertility in USA and Israel (Vaginal)
  • 01 Aug 2014 Teva completes a phase I bioequivalence trial in healthy postmenopausal women in USA (NCT02092571)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top